AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML

AB Science completed Step 3 of Phase 1 evaluating AB8939 + venetoclax in refractory/relapsed AML (n=6; 16 mg/m² and 21.3 mg/m²). Results showed 67% ORR (4/6) and 100% disease control rate with no dose-limiting toxicities observed, supporting selection of the recommended Phase 2 dose. The company will advance to Step 4 testing AB8939 + venetoclax + azacitidine and plans an expansion cohort of ~15 patients at the RP2D.

Analysis

The real signal is not the headline response rate; it is the possibility that AB8939 can re-sensitize venetoclax-refractory AML. If that holds, AB Science is not just selling another salvage drug — it could become a combination partner that extends the commercial life of venetoclax in the hardest-to-treat end of the market, which is more valuable than a modest standalone niche. That also means the economic prize is probably larger for whichever larger platform can ultimately license or co-develop this, not for the microcap itself.

Near term, the stock can trade sharply on perceived de-risking, but this is still an n=6 signal and the next leg is financing, not science. The likely second-order effect is dilution into strength: a positive Step 4 launch and expansion cohort should improve partnering odds, but it does not remove the need for capital before a credible registration path. Over 1-3 months, the key catalyst is whether the triple-combo step preserves tolerability; over 6-18 months, the question is durability and depth, especially MRD negativity and relapse kinetics in TP53/complex-karyotype disease.

The contrarian miss is that the most favorable subset here is also the noisiest: early responses in ultra-high-risk AML often evaporate when follow-up lengthens. The right falsifier is not a softer press release; it is an expansion readout showing ORR compressing below ~40%, early marrow toxicity emerging with azacitidine, or short response duration despite initial blasts falling. If that happens, this re-rates from platform story to speculative one-off and the move should be faded.

Key Decisions for Investors

• Do not chase ABSCF on the first spike; wait for post-news consolidation and evidence the market is not just pricing a financing pop. If forced to express, keep size small and treat it as event-driven optionality, not a core biotech long.
• Buy ABSCF only on a pullback after the initial gap if Step 4/expansion initiation is confirmed and volume remains constructive; invalidation is any sign the next cohort shows ORR <40% or meaningful hematologic toxicity.
• Use XBI as a hedge against broad small-cap biotech beta if taking an ABSCF starter position; the trade is idiosyncratic alpha versus sector noise, not a macro biotech view.
• Set a hard alert for the first expansion readout and/or conference abstract: if responses remain durable in the TP53/complex-karyotype group, add; if not, reduce immediately.
• No direct short in the obvious AML incumbents yet; the more likely medium-term beneficiary of a positive result is a larger partner/licensor, so the clean trade is ABSCF event optionality, not a crowded pair.